The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Bluebird bio Inc (NASDAQ: BLUE) was $4.97 for the day, down -0.20% from the previous closing price of $4.98. In other words, the price has decreased by -$0.20 from its previous closing price. On the day, 0.69 million shares were traded.
Ratios:
Our analysis of BLUE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.29 and its Current Ratio is at 0.55.
BofA Securities Downgraded its Buy to Neutral on November 15, 2024, whereas the target price for the stock was revised from $3 to $0.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 03 ’25 when Colvin Richard A sold 584 shares for $3.92 per share. The transaction valued at 2,289 led to the insider holds 7,610 shares of the business.
Klima Thomas J sold 500 shares of BLUE for $1,960 on Mar 03 ’25. The insider now owns 7,878 shares after completing the transaction at $3.92 per share. On Mar 03 ’25, another insider, Obenshain Andrew, who serves as the President and CEO of the company, sold 921 shares for $3.92 each. As a result, the insider received 3,610 and left with 18,327 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.47.
Stock Price History:
Over the past 52 weeks, BLUE has reached a high of $28.60, while it has fallen to a 52-week low of $3.20. The 50-Day Moving Average of the stock is 13.42%, while the 200-Day Moving Average is calculated to be -35.11%.
Shares Statistics:
A total of 9.79M shares are outstanding, with a floating share count of 9.69M. Insiders hold about 1.08% of the company’s shares, while institutions hold 37.45% stake in the company.
Earnings Estimates
Bluebird bio Inc (BLUE) is currently under the scrutiny of 2.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.69, with high estimates of $0.4 and low estimates of -$1.78.
Analysts are recommending an EPS of between -$4.2 and -$11.28 for the fiscal current year, implying an average EPS of -$7.74. EPS for the following year is -$5.0, with 1.0 analysts recommending between -$5.0 and -$5.0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $68.8M to a low estimate of $30M. As of the current estimate, Bluebird bio Inc’s year-ago sales were $16.1MFor the next quarter, 3 analysts are estimating revenue of $68.3M. There is a high estimate of $84.6M for the next quarter, whereas the lowest estimate is $52M.
A total of 4 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $316.84M, while the lowest revenue estimate was $150.05M, resulting in an average revenue estimate of $227.17M. In the same quarter a year ago, actual revenue was $83.81MBased on 1 analysts’ estimates, the company’s revenue will be $224.7M in the next fiscal year. The high estimate is $224.7M and the low estimate is $224.7M.
